Skip to main content

Advertisement

Table 4 Adverse events reported in at least 10% of patients in any treatment group.

From: Assessment of strategies for switching patients from olanzapine to risperidone: A randomized, open-label, rater-blinded study

  Abrupt (n= 40) Gradual 1 (n= 39) Gradual 2 (n= 42) All treatments (n= 121)
Patients with any adverse event 73% 90 % 79% 80%
Insomnia 23% 13% 24% 20%
Anxiety 18% 13% 14% 15%
Sedation 5% 18% 12% 12%
Somnolence 10% 10% 10% 10%
Headache 3% 10% 7% 7%
Aggravated psychosis 13% 0 5 6%